Search results
Showing 1 to 15 of 33 results for pomalidomide
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
NICE is unable to make a recommendation on daratumumab (Darzalex) with pomalidomide (Imnovid) and dexamethasone for treating relapsed or refractory multiple myeloma because Janssen did not provide an evidence submission.
Show all sections
Sections for TA726
NICE is unable to make a recommendation on pomalidomide (Imnovid) with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Celgene did not provide an evidence submission.
Show all sections
Sections for TA602
In development Reference number: GID-TA11201 Expected publication date: 11 February 2026
In development Reference number: GID-TA10979 Expected publication date: 11 March 2026
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
In development Reference number: GID-TA11203 Expected publication date: 08 April 2026
Discontinued Reference number: GID-TA10353